- RSI is at a high level of 71. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The Pfizer (PFE)vaccine news does not take away the need for rapid testing, since it may be a year before vaccines are available to all risk groups notes Brian Weinstein, a health-care sector analyst at William Blair. Plus it’s not clear how many people will use the vaccine, because of safety concerns, says Deutsche Bank market strategist Marion Laboure. The good news is that Biden will likely preserve and expand the Affordable Care Act which is good for biopharma companies, notes Jefferies an...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time.
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
Acadia Pharmaceuticals (NASDAQ: ACAD) has taken investors on something of a wild ride so far in 2020. There have been multiple share price swings of 20% or more this year. After a nice rise in recent weeks, Acadia could be headed for yet another downturn.
Acadia (ACAD) delivered earnings and revenue surprises of -42.11% and 1.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020.
NEW YORK, NY / ACCESSWIRE / November 4, 2020 / ACADIA Pharmaceuticals, Inc.